Ironwood CEO stepping down to run spinoff biotech – The Boston Globe
Ironwood has developed medicines for gastrointestinal diseases, including Linzess, and is among a relatively small group of Cambridge biotechs with approved drugs on the market. But the 21-year-old company, under pressure from an activist investor to increase the value of its stock, announced in May that it planned to split into two independent publicly traded firms. Terrance G.
Name: Peter Hecht
Continent: North America
Country: USA
Company: Ironwood Pharmaceuticals
Branch: Pharma
Position: CEO
Reason: Resigned
New Company: Cyclerion Therapeutics
New Position: CEO
Announcement Date: January 03, 2019, 11:00pm
Resignation Date: January 03, 2019, 11:00pm